HMG-box containing protein 1 (HBP1) is a member of the high mobility group (HMG) of chromosomal proteins. Since HBP1 exhibits tumor-suppressor activity in nonmyeloid tissues, we examined the effects of ectopic overexpression of HBP1 upon the growth and differentiation of myeloid cells. We prepared transient and stable transfectants of the myeloblast cell line K562, which overexpress HBP1 mRNA and protein. HBP1 transfectants displayed slower growth in cell culture and reduced colony formation in soft agar, retardation of S-phase progression, reduced expression of cyclin D1 and D3 mRNAs and increased expression of p21 mRNA. HBP1 transfectants also underwent increased apoptosis, as demonstrated by morphology and binding of Annexin V. Fas ligand mRNA levels were increased in HBP1 transfectants, suggesting involvement of the Fas/Fas ligand pathway. HBP1 overexpression enhanced differentiation of K562 cells towards erythroid and megakaryocyte lineages, as evidenced by increased hemoglobin and CD41a expression. Overexpression of HBP1 modulated mRNA levels for myeloid-specific transcription factors C/EBPa, c-Myb, c-Myc, and JunB, as well as lineage-specific transcription factors PU.1, GATA-1, and RUNX1. These findings suggest that in myeloid cells HBP1 may serve as a tumor suppressor and a general differentiation inducer and may synergize with chemical differentiating agents to enhance lineage-specific differentiation.
Introduction
HMG-box containing protein 1 (HBP1) was first identified in rat brain, on the basis of its ability to suppress the potassium transport-defective phenotype of mutant Saccharomyces cerevisiae.
1 HBP1 was recognized to be a member of the high mobility group (HMG) protein family, since it contains a 70 amino-acid DNA-binding domain known as an HMG-box, characteristic of these proteins. 2 HMG proteins are transcription factors that are widely distributed among eukaryotic cells and have diverse functions. [2] [3] [4] [5] [6] [7] [8] [9] In the course of a yeast one-hybrid search for novel factors that bind to the MPO promoter and modulate MPO promoter activity, we identified HBP1, as an MPO promoter-binding protein. 10 We demonstrated by transfection experiments that HBP1 enhances MPO promoter activity. We isolated and cloned the cDNA for the human HBP1 gene (GenBank Accession Number AF019214, October 2, 1997). The corresponding human HBP1 mRNA sequence contains a single open reading frame, which codes for a protein composed of 514 amino acids. In addition to the HMG box-like sequence, which is the DNA-binding region, the amino-acid sequence of HBP1 includes two pocket protein-binding sequences: an LXCXE site and an IXCXE site. This protein also contains a 28 amino-acid sequence that shows 86% homology with a transcriptional activation domain previously demonstrated in rat HBP1. 11 This activation domain is flanked by two putative repressor domains (identified by comparison with the rodent HBP1 gene). The presence of these sequences suggests that human HBP1 may activate and/or repress transcription of other genes, in part through interaction with RB.
Information developed by ourselves and other investigators indicates that HBP1 is an important regulator of the cell cycle, cell cycle exit, apoptosis and terminal differentiation in a variety of tissues and cell types. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] In specific nonmyeloid tissues it partners with the tumor-suppressor RB and other pocket proteins, [11] [12] [13] inhibits the p47phox gene, 22 targets downstream factors such as N-Myc, Histone H1, and cyclin D1, 23 and alters chromatin structure by bending DNA and recruiting histone deacetylase cofactors. 17 However, its role in myeloid cell growth and differentiation remains to be elucidated.
Mounting evidence from nonmyeloid tissues suggests that HBP1 may be a tumor suppressor. For example, HBP1 inhibits G1 progression in fat and muscle cells 12 and blocks the Wnt pathway, 21 which is important in cancer. The HBP1 gene lies within the 7q31 chromosomal region that is frequently deleted or translocated in cancers. 10 Yee et al 23 have recently isolated variants of HBP1 in breast cancers and myeloid leukemias, suggesting a possible role of HBP1 in human neoplasia. However, the role of HBP1 in pathogenesis of myelodysplasias and myeloid leukemias remains to be elucidated.
To explore the role of HBP1 in regulating the growth of myeloid cells and to study its possible tumor-suppressor activity we overexpressed HBP1 in the myeloblast cell line K562 and studied its effect upon cell growth and differentiation. Our results show that overexpression of HBP1 in myeloblasts leads to growth arrest and apoptosis and acts as a general inducer of differentiation.
Materials and methods

Materials
The human cell line K562 (erythroleukemic) was obtained from the American Type Culture Collection (Rockville, MD, USA). Polyclonal rabbit antibody against HBP1 was prepared as previously described. 10 The pBudCE4.1 vector, Zeocin antibiotic, and DMRIE-C transfection reagent were obtained from Invitrogen (Carlsbad, CA, USA). Anti-CD41a (FITC-conjugated) and other antibodies used in flow cytometric analyses were obtained from BD Biosciences (San Jose, CA, USA). SYBR s Green PCR Master Mix was from Applied Biosystems (Foster City, CA, USA).
Zeocin-resistance gene for Zeocin selection of stable cells. Two types of constructs containing HBP1 were established as follows: HBP1/CMV (with HBP1 driven by a CMV promoter) was prepared by ligating HBP1 to pBudCE4.1 at the multiple cloning site of the CMV promoter at SalI and BamHI restriction sites. HBP1/EF1a (with HBP1 driven by an EF1a promoter) was prepared by ligating HBP1 to modified pBudCE4.1 (cutting off the whole segment containing the CMV promoter) at the multiple cloning site of the EF1a promoter at NotI and XhoI restriction sites. All of the constructs were verified by sequencing. The control vector employed was pBudCE4.1/LacZ/CAT (hereafter referred to as 'CAT vector'). The linearization sites of these constructs were: NheI for HBP1/ CMV, FspI for HBP1/EF1a, and BspHI for CAT vector. All constructs were expanded in Escherichia coli DH5a and plasmids were purified using a Maxi-prep kit (Qiagen, Valencia, CA, USA).
Cell culture, establishment of stable cell lines and transfection K562 cells were maintained in RPMI 1640 (GibcoBRL, Gaithersburg, MD, USA) supplemented with 1% L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% heat-inactivated fetal calf serum, and grown in humidified 5% CO 2 at 371C. Exponentially growing cells were used for all experiments. For determination of growth rate, cells were diluted at an initial concentration of 0.2 Â 10 6 cells/ml in complete medium and aliquots were removed daily for determination of cell concentration. In experiments addressing induction of differentiation, cells at an initial concentration of 0.2 Â 10 6 cells/ml were incubated in complete medium with or without 30 mM hemin or 10 ng/ml TPA (Sigma Chemical Co, St Louis, MO, USA). For growth in soft agar, cells were cultured in RPMI-1640 medium containing 0.3% Bectar agar, and 20% fetal calf serum. After 10 days colonies containing more than 50 cells were enumerated using an inverted microscope.
To establish stable HBP1-overexpressing cell lines, 1.6 Â 10 7 K562 cells were transfected by the linearized constructs (32 mg each) with 48 ml DMRIE-C reagent (Invitrogen). Stably transfected cells, except K562 cells only, were selected in culture medium containing 200 mg/ml of Zeocin. Colonies (bulk cultures) of Zeocin-resistant cells were obtained approximately 14 days after selection and were propagated. HBP1-overexpressing stable cell lines were screened by quantitative realtime RT-PCR (QRT-PCR), and further confirmed by Western blotting. Control cell lines transfected with CAT vector were screened using a chloramphenicol acetyltransferase (CAT) enzyme-linked immunosorbent assay kit (Boehringer Mannheim), according to the manufacturer's specifications. These bulk cultures of stably transfected cells were then subjected to limiting dilution to isolate individual clones. Eight clones were obtained from each of the bulk cultures. Two representative clones derived from each construct were fully analyzed and described in this communication. These were designated HBP1/ CMV-1, HBP1/CMV-2, HBP1/EF1a-1, HBP1/EF1a-2, CAT-1, and CAT-2.
Preparation of cell lysates and Western blot analysis
Total cell extracts from 10 7 K562 cells or stable transfectants were prepared as described by Shih et al. 13 The cell lysates 
Apoptosis assay
Apoptosis assays were performed using an Annexin V-FITC detection kit I (BD Biosciences Pharmingen). The cells were analyzed using a FACScan flow cytometer and data were evaluated using WinMDI 2.8 research software. The results were expressed as percentage of apoptotic Annexin V-FITC positive cells with respect to total cells counted.
May-Grunwald-Giemsa staining, and benzidine staining
Approximately 5 Â 10 4 cells were spun onto a microscope slide in a Cytospin 3 cytocentrifuge (Shandon, Thermo Electron Corporation, Pittsburgh, PA, USA). After air drying, slides were stained with May-Grunwald-Giemsa stain (Sigma, St Louis, MO, USA).
The percentage of cells staining for hemoglobin was estimated by staining with benzidine/H 2 O 2 essentially as described. 24 At least 500 cells were counted and the number of cells containing oxidized tetramethylbenzidine (visualized as bright blue-stained cells) was taken as indicative of peroxidase activity, thus reflecting hemoglobin production.
Flow cytometric assessment of cell surface antigen expression
Expression of cell surface antigens in differentiating cells was determined by flow cytometry. K562 cells (10 6 cells/sample) were washed and resuspended in PBS. Fluorescent-conjugated antibody (10 ml) against the appropriate cell surface antigens (eg FITC-conjugated mouse antibody CD41a) or isotype-matched control IgG were added to the cell suspension to stain the cells. After incubation at room temperature for 30 min, the stained cells were washed and fixed with formaldehyde. Cell fluorescence was measured on a FACScan flow cytometer (BD Biosciences).
Quantitative real-time RT-PCR
Total RNA was isolated using the Trizol reagent (Invitrogen), and 1 mg of RNA was subjected to reverse transcription using ThermoScriptt RT (Invitrogen). Specific primers were designed using Primer3 software (MIT Whitehead Institute, http:// www.basic.nwu.edu/biotools/Primer3.html) (see Supplementary Information). In total, 40 cycle, two-step, real-time PCR was performed on an iCycler iQ multicolor real-time PCR detection system (Bio-Rad). Each sample was run in triplicate. Cycle threshold (C t ) values were obtained and relative RNA expression was determined using the formula Relative Expression ¼ 2 À(DDCt) Â 100, where DDC t ¼ (C t gene of interestÀC t GAPDH in experimental sample)À(C t gene of interestÀC t GAPDH in untransfected, untreated K562 cells sample). Amplicon size and reaction specificity were confirmed by agarose gel electrophoresis.
Co-immunoprecipitation
K562 cells were transiently cotransfected with pRC/RB and HBP1/EF1a. Cell lysates from 10 7 cells were prepared as described above. After measuring the protein concentration, 1 mg of cell lysate was precleared using protein A-or protein G-Sepharose beads (Santa Cruz) before antibodies were added. Anti-HBP1 or anti-RB (or other) antibody and beads were added to the precleared cell lysate and incubated at 41C overnight with gentle agitation. Bound proteins were washed, centrifuged, the supernatant removed and the immunocomplexes resuspended in sample buffer containing b-mercaptoethanol; subsequently 200 mg aliquots of proteins were analyzed by Western blotting. K562 cells transfected with only the CAT vector served as the negative control.
Results
Establishment of stable transfectants of K562 cells that overexpress HBP1
We have previously transiently transfected myeloid cell lines with HBP1-expressing plasmids and have demonstrated increased HBP1 RNA and protein levels in the transfected cells. 10 However, in order to study the effect of overexpression of HBP1 on myeloid cell growth and differentiation, stable transfectants were prepared. To prepare clones with limited overexpression of HBP1 we took advantage of our observation that the CMV promoter produced lower levels of HBP1 expression than did the EF1a promoter. Hence, we prepared four sets of parallel cultures of K562 cells, as descried in Materials and methods: (1) cells transfected with HBP1/CMV; (2) cells transfected with HBP1/EF1a; (3) cells transfected with CAT vector; and (4) untransfected K562 cells. Figure 1 shows diagrams of the HBP1 expression vectors HBP1/CMV and HBP1/EF1a.
Bulk populations of transfected cells were prepared and individual clones were isolated through single cell limiting dilution from these bulk populations. Expression of HBP1 was screened by Western blotting and QRT-PCR. Eight clones were selected from each bulk population and two representative clones prepared from each of the constructs were fully studied and described in this communication.
HBP1 RNA expression in the HBP1/CMV clones ( Figure 2a ) was increased by about 40-50-fold compared with that in untransfected K562 cells, while that in the HBP1/EF1a clones was increased by 80-100-fold. 
Overexpressed HBP1 protein interacts with RB in K562 cells
Since HBP1 protein contains pocket protein-binding motifs, and since previous studies in fat and muscle cells had suggested that HBP1 in those tissues may interact with RB and other factors that regulate the cell cycle and cell differentiation, we investigated the interactions between HBP1 and RB in K562 cells that were overexpressing these proteins. When those cells were transiently cotransfected with RB and HBP1, immunoprecipitation of RB co-immunopurified HBP1, as demonstrated by a Western blot with an HBP1 antibody ( Figure 3a, lane 2) , while immunoprecipitation with a control antibody (against AP-1) did not bring down HBP1 under these conditions (Figure 3a, lane 3) . HBP1 migrates in gels at a position equivalent to 80 kDa, which is higher than expected from its molecular weight, but similar to the figure observed by other investigators. 12 Likewise, when K562 cells were cotransfected with RB and HBP1, immunoprecipitation of HBP1 coimmunopurified RB, as recognized by a Western blot with an RB antibody ( Figure 3b, lane 1) , and immunoprecipitation with a control antibody (against AP-1) did not bring down RB under these conditions (Figure 3b, lane 3) . (The antibody employed precipitates total RB with a molecular weight of 110 kDa.) These data confirm that RB and HBP1 can form a specific complex in K562 cells.
HBP1 inhibits cell proliferation in K562 cells
To analyze whether expression of HBP1 affects the proliferation of K562 cells, all clones were plated and allowed to grow in standard media for 4 days. The HBP1-expressing clones showed a reduced proliferation rate compared with nontransfected cells or the CAT-transfected clone, as measured by total number of cells/ml (Figure 4a ). Cells with the highest HBP1 expression (HBP1/EF1a clones) showed the slowest growth rate compared with the other clones. Changes in bulk culture growth rates followed similar kinetics as did the corresponding single clones (data not shown). These findings suggest that HBP1 inhibits cell proliferation in K562 cells.
K562 cells and all clones derived from them were also tested for growth in a colony forming soft agar assay. K562 cells and CAT clones formed more and larger colonies while HBP1 overexpressing clones formed fewer and smaller colonies (Figure 4b and c).
HBP1 inhibits cell cycle progression
Cell proliferation is determined, in part, by the relative balance between cell cycle progression and apoptosis. To address the effect of overexpressed HBP1 in the context of cell cycle regulation, the cell cycle profiles were determined by a BrdU incorporation assay. K562 cells overexpressing HBP1 showed an increase in cells residing in the G0/G1 phase (41-44%) in HBP1-overexpressing cells compared with 28-31% in cells transfected with the CAT vector or non-transfected K562 cells (Table 1) . Likewise, HBP1-overexpressing cells showed a decrease in percentage of cells in S phase (40-46%) compared with 55-59% in CAT-transfected and nontransfected K562 cells, suggesting that the rate of BrdU incorporation in S phase was also decreased (Table 1 ). These results indicate that HBP1 inhibits cell cycle progression in G1 phase in K562 cells.
HBP1 decreases the expression of specific cyclins which regulate G0/G1-to-S progression To explore the mechanisms by which HBP1 overexpression slows cell cycle progression, we examined the expression of multiple cell cycle regulatory genes in HBP1-overexpressing cells. Genes examined include cyclins D1, D3, and E as well as CDK2 and CDK4, CDK inhibitors p21, p27, and p16. Total RNAs from HBP1-overexpressing cell lines were analyzed by QRT-PCR. Overexpression of HBP1 decreased the expression of mRNAs for cyclin D1 and D3, but not the E cyclins and increased the message level of p21 ( Figure 5 ). These findings suggest that HBP1 effects upon cell cycle progression may be mediated by changes in cyclin expression during G1. No significant changes were seen in mRNAs corresponding to CDK2, CDK4, p53, p16, or p27 or in the expression of the housekeeping gene GAPDH. All cells overexpressing HBP1 showed a marked increase in expression of p21 mRNA following TPA treatment (data not shown). This observation is consistent with prior evidence that p21 enhances differentiation in K562 cells. One pathway for the induction of apoptosis involves the interaction of Fas (CD95) with its ligand FasL (CD95L). As a first step to exploring this pathway we examined the effect of HBP1 overexpression on mRNA levels for FasL. Figure 7 shows data comparing the levels of mRNA for FasL in the four groups of K562 cell clones. High level HBP1 overexpression (HBP1/EF1a clones) induces an increase in FasL mRNA (normalized to Expression of cell cycle-related genes in K562 cells and stably transfected clones, relative to expression levels of the GAPDH gene measured by QRT-PCR. Values are based on three independent experiments with triplicate measurements for each.
n Po0.05 compared with untransfected K562 cells. CCND1 ¼ cyclin D1; CCND3 ¼ cyclin D3; CCNE1 ¼ cyclin E1. To confirm that HBP1 overexpression induced increased differentiation of K562 cells toward the erythroid lineage we carried out benzidine staining to demonstrate the presence of hemoglobin in the cells. While only about 2% of untransfected K562 cells or CAT clones showed erythroid differentiation, as evidenced by benzidine positivity, about 30% of HBP1-overexpressing cells were benzidine positive even in the absence of the inducing agent hemin (Figure 8 ). In this respect there was no significant difference among the various HBP1-overexpressing clones (HBP1/CMV-1 or 2, and HBP1/EF1a-1 or 2). HBP1-overexpressing cells also showed increased hemoglobin expression after hemin treatment compared with untransfected K562 cells treated with the same agent. Specifically, about 50-60% of HBP1-overexpressing K562 cells treated for 24 h with hemin were benzidine positive (Figure 8 ), compared with 20-25% for untransfected K562 cells treated with hemin. Interestingly, while increasing the expression of megakaryocytic markers (see data below), TPA treatment tended to reduce hemoglobin expression in HBP1-overexpressing K562 cells compared with uninduced cells (Figure 8 ), although the latter change was not statistically significant. Cells examined after 48, 72, or 96 h of hemin or TPA treatment showed hemoglobin expression patterns similar to HBP1 and myeloid cell growth and differentiation CJ Yao et al those of cells examined after 24 h of these treatments (data not shown). These findings indicate that HBP1 overexpression in K562 cells induced differentiation toward the erythroid lineage and promoted or enhanced hemoglobin production induced by hemin in these cells.
To further characterize the ability of HBP1 to induce differentiation of K562 cells along either erythroid or megakaryocyte lineages, four-color immunofluorescence flow cytometry was carried out using fluorescent conjugated mAbs specific for expression of surface markers. HBP1 overexpression produced a number of effects consistent with differentiation of these cells toward erythroid and megakaryocytic lineages and away from granulocyte/monocyte lineages. These changes (Table 2 ) included a loss of granularity of the cells, a progressive loss of CD45 expression (CD45 expression is low in erythroid and platelet precursors and high in cells of the granulocytic lineage), and a decrease in the granulocytic marker CD13 and in the blast marker CD34. On the other hand, increased expression of the erythroid marker CD71 (in the absence of CD33 expression), and of platelet markers CD41a and CD61 was observed. Figure 9 shows CD41a expression in the different clones. HBP1 induced an increase in CD41a expression in the absence of TPA treatment and caused higher levels after TPA treatment than were seen in the absence of HBP1 overexpression. Interestingly, even hemin treatment caused some increase in CD41a expression and this was enhanced by HBP1 overexpression (data not shown). This observation presumably reflected the multipotential nature of K562 cells, which have the ability to differentiate along both erythroid and megakaryocytic lineages.
HBP1 influences expression of lineage-specific transcription factors involved in differentiation
The process of hematopoietic differentiation is orchestrated at the molecular level by a complex network of transcription factors that act by regulating the expression of sets of target genes. In order to investigate the relationship of HBP1 with other key transcription factors in regulating erythroid and megakaryocytic development, we used QRT-PCR to analyze expression of a number of such regulatory genes to determine if they are upregulated or downregulated as a result of HBP1 overexpression. Figure 10a shows the normalized expression of mRNAs for GATA-1, RUNX1, PU.1 in the four groups of clones derived from K562 cells. GATA-1 is a gene which is activated very early in erythroid development and plays a key role in erythroid differentiation. 26 Enforced GATA-1 expression in myeloid cell lines promotes erythroid, megakaryocytic, or combined differentiation, depending on the cell type. 27 GATA-1 is scarcely expressed in quiescent erythroid progenitors, but is rapidly induced when these cells are induced to erythroid differentiation by erythropoietin and then progressively accumulates during erythroid maturation, being abundantly expressed during all stages of erythroid maturation. We found that GATA-1 was upregulated to a small extent in HBP1-overexpressing cells. GATA-1 levels increased in untransfected K562 cells after hemin or TPA treatment. However, in HBP1-overexpressing cells GATA-1 levels increased to a greater extent after the cells were induced with either hemin or TPA (data not shown).
RUNX1, a transcription factor involved in megakaryocytic differentiation 27 was upregulated as well in HBP1-overexpressing cells (Figure 10a ). RUNX1 mRNA levels increased to a greater extent after the cells were induced with TPA (but not with hemin) (data not shown). Interestingly, the mRNA level of PU.1, an important transcription factor involved in granulocyte differentiation, was slightly reduced by HBP1 overexpression (Figure 10a ). Hemin treatment reduced PU.1 expression more in HBP1-overexpressing cells, while TPA treatment restored PU.1 expression to a level similar to that in K562 cells or the CAT control (data not shown). Transcripts of C/EBPa, which is thought to be involved mainly in myeloid cell differentiation, 28 were increased, surprisingly, up to 10-or 12-fold in high HBP1-overexpressing cells (HBP1/EF1a-1 or 2) and to a lesser extent in HBP1/CMV clones. Expression of another transcription factor, JunB, which is known for its regulation of myeloid differentiation 29 was also increased significantly in HBP1-overexpressing cells (Figure 10b ). JunB is known to negatively regulate cell proliferation, in part by decreasing cyclin D1 expression. 30 After hemin or TPA treatment, mRNAs for C/EBPa and JunB were upregulated to a dramatic extent (data not shown). Expression levels of the transcription factors c-Myb 31 and c-Myc are known to decline during myeloid differentiation. The normalized levels of the mRNA for both of these genes were significantly reduced in HBP1-overexpressing cells both in the absence (Figure 10b ) and in the presence (data not shown) of inducing agents TPA and hemin.
Discussion
Our studies demonstrate that overexpression of HBP1 in K562 cells slows cell growth in standard tissue culture and soft agar, increases apoptosis, and induces the cells to differentiate along both erythroid and megakaryocytic pathways.
Inhibition of cell growth appears to result from arrest of the cell cycle at the G0/G1 phases, resulting in reduced percentage of cells in S phase. This appears to be a general property of HBP1, since Tevosian et al 12 observed a similar effect in fat and muscle cells in which HBP1 was overexpressed and Shih et al 13 showed that transgenic mice in which HBP1 is modestly overexpressed showed delayed progression of liver cells through G1 to S following partial hepatectomy. We found that inhibition of growth of K562 cells by HBP1 is accompanied by, and presumably mediated, in part, by reduction in mRNA levels for specific modulators of the G1-to-S transition, including cyclin D1, cyclin D3, and c-Myc. Also, expression of the antiproliferative cyclin-dependent kinase inhibitor p21 WAF1/CIP1 was increased in HBP1-overexpressing cells. p21 inhibits G1 progression by blocking the activity of cyclin-dependent kinases, providing an additional mechanism by which HBP1 may retard G1 progression.
Our findings concerning the inhibition of cyclin D1 and c-Myc expression by HBP1 in K562 cells are in agreement with those of Sampson et al 21 who showed that in the human embryonic kidney cell line HEK293, HBP1 overexpression repressed Wnt-b-catenin activation of the cyclin D1 promoter as well as endogenous expression of cyclin D1 and c-Myc genes, both of which are targets of the Wnt pathway.
Our morphologic evidence that HBP1 overexpression in K562 cells increases the number of apoptotic cells, is supported by data showing an increase in Annexin V positivity in cells overexpressing HBP1. Levels of FasL were increased in HBP1-overexpressing cells, suggesting that binding of FasL to Fas may trigger apoptosis in these cells. 32 However, expression of other preapoptotic factors examined was not consistently altered in HBP1-overexpressing cells. Thus, further work will be necessary to define the molecular mechanisms by which HBP1 stimulates apoptosis in K562 cells.
HBP1 overexpression also appears to induce differentiation of K562 cells. Whereas most pro-differentiation factors promote differentiation toward only one lineage, HBP1 appears to possess the unusual property of inducing differentiation along both erythroid and megakaryocytic pathways. Furthermore, HBP1 also enhances lineage-specific differentiation induced by chemical agents such as TPA or hemin. However, although HPB1 induces differentiation of K562 cells along both erythroid and megakaryocytic pathways, it is not simply a non-specific inducer of differentiation, since it does not appear to promote differentiation of K562 cells toward granulocytes or monocytes. Thus, overexpression of HBP1 in K562 cells results in loss of cell granularity (determined by side scatter), as well as loss of surface CD45 expression and decrease in expression of the myeloid marker CD13 (data not shown). While the mechanisms by which HBP1 induces bilineage differentiation remain to be elucidated, Kohmura et al 33 recently demonstrated that treatment of K562 cells with the specific tyrosine kinase inhibitor STI571 (an inhibitor of Abl kinase) induced multilineage differentiation as evidenced by increased expression of megakaryocytic markers CD41a and CD42, the erythroid marker glycophorin A, and myeloid markers CD11b and CD13. This agent appeared to act in part by inducing phosphorylation of p38 mitogen-activated protein kinase (MAPK) and dephosphorylation of extracellular signal-related kinase (ERK) in K562 cells. Xiu et al 20 recently demonstrated that MAPK stabilizes HBP1, suggesting that HBP1 expression might be one factor responsible for multilineage differentiation in both systems.
While the molecular mechanisms by which HBP1 induces erythroid and megakaryocytic differentiation of K562 cells remain to be determined, our data indicate that HBP1 overexpression induces significant changes in levels of mRNAs for a number of important transcription factors involved in differentiation of myeloid cells. mRNAs for C/EBPa, JunB, GATA-1, and RUNX1 are increased in K562 cells overexpressing HBP1, whereas levels of mRNAs for c-Myb, c-Myc, and PU.1 are decreased. Most of these changes agree with expectations, based upon previous literature regarding myeloid differentiation. However, an exception is C/EBPa. Radomska et al 34 have previously shown that overexpression of this factor in K562 cells induces granulocytic differentiation, whereas our findings indicate that HBP1 increases C/EBPa mRNA levels while inducing erythroid and megakaryocytic differentiation and reducing expression of myeloid markers. Clearly, the overall context of the cell and the global changes induced by HBP1 rather than the level of one particular transcription factor determine the direction of differentiation. An important aspect of HBP1 is its potential tumor-suppressor activity. As mentioned above, both our data and those of Sampson et al 21 indicate that HBP1 inhibits G1 progression and blocks the Wnt pathway, which is important in cancer. The fact that the HBP1 gene lies at a chromosomal location 7q31.1, which is frequently deleted in cancer, 10 provides further suggestive evidence for a tumor-suppressor function of HBP1. Recent data that the HBP1 gene is frequently mutated in breast cancers 23 and leukemias 35 further support this possibility. Our data showing reduced colony formation in soft agar also supports the possible tumor-suppressor activity of HBP1. Furthermore, the ability of HBP1 to partner with RB and to increase the activity of p21 provides additional mechanisms by which HBP1 may exert tumor-suppressor activity.
Knowledge of how HBP1 acts to modulate tissue-specific gene expression, to regulate cell proliferation, and to control terminal myeloid differentiation should provide insights into the overall control of growth and maturation of normal and leukemic myeloid cells, and may ultimately lead to better therapies for leukemias and other proliferative disorders of white blood cells.
